Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVINZA vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AVINZA (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the CNS, producing analgesia by altering pain perception and emotional response to pain.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of opioid-experienced patients with moderate to severe chronic pain requiring daily, around-the-clock opioid therapy for an extended period of time
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Oral, 30 mg once daily (q24h) for opioid-naïve patients; titrate based on response. Maximum daily dose 160 mg. Administer with food to minimize peak effects.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life of morphine is approximately 1.5-2 hours; however, due to the extended-release formulation, the effective half-life is prolonged to about 9-11 hours, allowing once-daily dosing.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via glucuronidation by UGT2B7 to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); minor CYP2C9 involvement.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal (approximately 90% as morphine metabolites, mainly morphine-3-glucuronide and morphine-6-glucuronide); biliary/fecal excretion accounts for less than 10%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 30-40% bound to plasma proteins, primarily albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 3-4 L/kg, indicating extensive tissue distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability of morphine is variable (approximately 20-40%) due to extensive first-pass metabolism; the extended-release formulation provides consistent absorption over 24 hours.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For GFR 30-59 m L/min: initiate at 50% of usual dose and titrate carefully; GFR <30 m L/min: initiate at 25% of usual dose; avoid in severe renal impairment (GFR <15 m L/min).
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A: initiate at 50% of usual dose; Class B: initiate at 25% of usual dose; Class C: avoid use.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not recommended in pediatric patients <18 years; safety and efficacy not established. For adolescent patients (≥18 kg), off-label use: 0.1-0.2 mg/kg/dose q4-6h PRN; extended-release formulations not intended for children.
Not approved for pediatric patients <18 years; safety and efficacy not established.
For patients ≥65 years: initiate at 50% of adult dose (15 mg once daily) and titrate cautiously due to increased sensitivity, reduced renal/hepatic function, and higher risk of respiratory depression. Consider lower starting doses and extended intervals.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of life-threatening respiratory depression; addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; interactions with CNS depressants; severe hypotension; gastrointestinal obstruction; seizure risk; impaired mental or physical abilities.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction; paralytic ileus; hypersensitivity to morphine sulfate.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid alcohol and alcohol-containing products (e.g., some mouthwashes, extracts) due to risk of dose dumping. Grapefruit juice may increase morphine bioavailability; limit intake. High-fat meals may delay absorption but not significantly alter overall exposure.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Prolonged use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid chronic use near term.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Morphine is excreted into breast milk; M/P ratio approximately 1:1. Infant exposure is dose-dependent; monitor for sedation, respiratory depression, and withdrawal. Use with caution; avoid in breastfeeding women with known infant risk factors.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Increased clearance and volume of distribution during late pregnancy may require dose adjustments. Use lowest effective dose for shortest duration. Avoid extended-release formulations near term; consider immediate-release morphine for acute pain management.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
AVINZA is an extended-release morphine formulation using the SODAS (Spheroidal Oral Drug Absorption System) technology, consisting of immediate-release and sustained-release beads. It must be taken whole; crushing or chewing can lead to rapid release and fatal overdose. Do not use in opioid-naïve patients; initiate with lower strengths if converting from other opioids. Monitor for signs of serotonin syndrome when co-administered with serotonergic drugs. Avoid alcohol consumption; ethanol can cause dose dumping.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take this medication exactly as prescribed; do not crush, chew, or break the capsules.,Swallow the capsules whole; if you have trouble swallowing, you may open the capsules and sprinkle the beads onto a small amount of soft food (e.g., applesauce) and swallow immediately without chewing.,Do not consume alcohol or any products containing alcohol while taking AVINZA, as it can lead to a dangerous increase in morphine levels.,This medication has a high risk of addiction, abuse, and misuse; store it safely and dispose of unused tablets properly.,Common side effects include constipation, nausea, drowsiness, and dizziness; report severe or persistent symptoms to your doctor.,Do not stop suddenly; withdrawal symptoms may occur; your doctor will guide you on tapering the dose.,Avoid driving or operating heavy machinery until you know how this medication affects you.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVINZA vs ABSTRAL, answered by our medical review team.
AVINZA is a Opioid Analgesic that works by AVINZA (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the CNS, producing analgesia by altering pain perception and emotional response to pain.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVINZA and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVINZA is: Oral, 30 mg once daily (q24h) for opioid-naïve patients; titrate based on response. Maximum daily dose 160 mg. Administer with food to minimize peak effects.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVINZA and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVINZA is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Prolonged use may cause neonatal o. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.